Entero Therapeutics, Inc. (NASDAQ:ENTO) Sees Large Drop in Short Interest

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 68,300 shares, a drop of 55.3% from the November 15th total of 152,900 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average daily volume of 471,000 shares, the short-interest ratio is presently 0.1 days.

Entero Therapeutics Stock Down 6.8 %

Entero Therapeutics stock traded down $0.04 during mid-day trading on Friday, reaching $0.58. The company’s stock had a trading volume of 72,549 shares, compared to its average volume of 364,733. The business’s 50 day simple moving average is $0.57 and its 200 day simple moving average is $0.86. Entero Therapeutics has a 12 month low of $0.19 and a 12 month high of $14.51.

Entero Therapeutics (NASDAQ:ENTO) last posted its earnings results on Monday, October 21st. The company reported ($3.37) earnings per share (EPS) for the quarter. Research analysts anticipate that Entero Therapeutics will post -1.13 earnings per share for the current fiscal year.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.